<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001336.v1.p1" parentStudy="phs001336.v1.p1" createDate="2017-03-22" modDate="2017-03-22">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Matt Zinter, MD</td><td>University of California, San Francisco, San Francisco, CA, USA</td></tr>
		<tr><td>Co-Investigator</td><td>Joe DeRisi, PhD</td><td>University of California, San Francisco and Chan Zuckerberg Biohub, San Francisco, CA, USA</td></tr>
		<tr><td>Funding Source</td><td>NIH/NICHD Pediatric Scientist Development Program (K12HD000850)</td><td>National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>Pediatric Blood and Marrow Transplant Consortium (PBMTC)</td><td>Pediatric Blood and Marrow Transplant Consortium, Los Angeles, CA, USA</td></tr>
		<tr><td>Funding Source</td><td>National Marrow Donor Program (NMDP) Amy Strelzer Manasevit Grant</td><td>National Marrow Donor Program, Minneapolis, MN, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>ECLS Survival in Pediatric HCT Recipient with Presumed Cardiac GVHD</StudyNameEntrez>
	<StudyNameReportPage>Extracorporeal Life Support Survival in a Pediatric Hematopoietic Cellular Transplant Recipient with Presumed Graft Versus Host Disease-Related Fulminant Myocarditis</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>We report the case of a 15-year-old female with hypodiploid pre-B acute lymphoblastic leukemia status post allogeneic hematopoietic stem cell transplantation (HCT) from a matched unrelated male donor who presented on transplant day +75 with cardiac arrest due to ventricular fibrillation associated with fulminant myocarditis. Using conventional diagnostics, an exhaustive search for microbial pathogens in the heart biopsy as well as nasopharynx, blood, urine, and endotracheal aspirate was performed but did not uncover a candidate pathogen. The family consented to a research study for the use of unbiased next-generation genomic sequencing for pathogen identification in the myocardial biopsy. DNA sequencing was performed on 1.5 x 10<sup>8</sup> sequencing pairs and no microbial pathogens were identified. Interestingly, a significant component of Y-chromosomal human DNA was identified, suggesting infiltration of at least 10 donor leukocytes per host cell. This finding is grossly consistent with the lymphocyte:myocyte ratio in the biopsy according to visual inspection at 40x magnification. This case merits discussion due to (1) her survival after 17 days of veno-arterial extracorporeal life support (ECLS) and (2) the possibility of cardiotropic graft versus host disease (GVHD).</p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Zinter MS, Barrows BD, Ursell PC, Kowalek K, Kalantar K, Cambronero N, DeRisi JL, Oishi P, Dvorak CC" title="Extracorporeal Life Support Survival in a Pediatric Hematopoietic Cellular Transplant Recipient with Presumed Graft Versus Host Disease-Related Fulminant Myocarditis" journal="Bone Marrow Transplantation. Under Review."/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Bone Marrow Transplantation"/>
		<Disease vocab_source="MESH" vocab_term="Hematopoietic Stem Cell Transplantation"/>
		<Disease vocab_source="MESH" vocab_term="Graft vs Host Disease"/>
		<Disease vocab_source="MESH" vocab_term="Myocarditis"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Matt Zinter, MD</AttName>
			<Institution>University of California, San Francisco, San Francisco, CA, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Joe DeRisi, PhD</AttName>
			<Institution>University of California, San Francisco and Chan Zuckerberg Biohub, San Francisco, CA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>NIH/NICHD Pediatric Scientist Development Program (K12HD000850)</AttName>
			<Institution>National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Pediatric Blood and Marrow Transplant Consortium (PBMTC)</AttName>
			<Institution>Pediatric Blood and Marrow Transplant Consortium, Los Angeles, CA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>National Marrow Donor Program (NMDP) Amy Strelzer Manasevit Grant</AttName>
			<Institution>National Marrow Donor Program, Minneapolis, MN, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="2" shortName="HMB-IRB-PUB-COL-MDS-GSO" longName="Health/Medical/Biomedical (IRB, PUB, COL, MDS, GSO)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NICHD</DacName>
      <DacFullName>NICHD-DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001336.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001336.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001336.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Health/Medical/Biomedical (IRB, PUB, COL, MDS, GSO)</ConsentName>
        <ConsentAbbrev>HMB-IRB-PUB-COL-MDS-GSO</ConsentAbbrev>
        <UseLimitation>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Requestor must provide documentation of local IRB approval.
Requestor agrees to make results of studies using the data available to the larger scientific community.
Requestor must provide a letter of collaboration with the primary study investigator(s).
Use of the data includes methods development research (e.g., development of software or algorithms).
Use of the data is limited to genetic studies only.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>
  <Documents>
    <Document phd="phd007214.1" type="protocol" createDate="2017-03-22" modDate="2017-03-22">
      <OrigName>protocolzinter03.18.17.txt</OrigName>
      <DisplayName>Protocol</DisplayName>
      <Description>Protocol</Description>
      <displayStatus>stage-2</displayStatus>
      <xmlStatus>develop</xmlStatus>
    </Document>
  </Documents>



</Study>

</Studies>

</GaPExchange>
